Weighing Treatment Risks and Rewards in Rare Disease Therapies
Patients with rare diseases often face difficult decisions when evaluating the risks and benefits of experimental treatments. Neurocrine Biosciences is developing a therapy that exemplifies this challenging calculus. The company must balance potential efficacy against possible adverse effects to gain regulatory and patient acceptance.
Related stories
UnitedHealth under IRS scrutiny for alleged tax avoidance · Healthcare systems
Eyepoint's wet AMD therapy misses key endpoint in trial · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk.” Browse more stories.